151 related articles for article (PubMed ID: 21754996)
1. Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.
Metzner KJ; Leemann C; Di Giallonardo F; Grube C; Scherrer AU; Braun D; Kuster H; Weber R; Guenthard HF
PLoS One; 2011; 6(7):e21734. PubMed ID: 21754996
[TBL] [Abstract][Full Text] [Related]
2. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
[TBL] [Abstract][Full Text] [Related]
4. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
[TBL] [Abstract][Full Text] [Related]
6. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Johnson JA; Li JF; Wei X; Lipscomb J; Irlbeck D; Craig C; Smith A; Bennett DE; Monsour M; Sandstrom P; Lanier ER; Heneine W
PLoS Med; 2008 Jul; 5(7):e158. PubMed ID: 18666824
[TBL] [Abstract][Full Text] [Related]
7. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Metzner KJ; Allers K; Rauch P; Harrer T
AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
9. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.
Toni TA; Asahchop EL; Moisi D; Ntemgwa M; Oliveira M; Masquelier B; Brenner BG; Wainberg MA
Antimicrob Agents Chemother; 2009 Apr; 53(4):1670-2. PubMed ID: 19171798
[TBL] [Abstract][Full Text] [Related]
10. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
11. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
14. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
15. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
[TBL] [Abstract][Full Text] [Related]
16. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
Metzner KJ; Scherrer AU; Preiswerk B; Joos B; von Wyl V; Leemann C; Rieder P; Braun D; Grube C; Kuster H; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
J Infect Dis; 2013 Oct; 208(7):1102-12. PubMed ID: 23847055
[TBL] [Abstract][Full Text] [Related]
17. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
[TBL] [Abstract][Full Text] [Related]
18. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Hance AJ; Lemiale V; Izopet J; Lecossier D; Joly V; Massip P; Mammano F; Descamps D; Brun-Vézinet F; Clavel F
J Virol; 2001 Jul; 75(14):6410-7. PubMed ID: 11413308
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
20. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
